Navigation Links
VIRxSYS and Lentigen Announce Litigation Settlement
Date:1/14/2008

GAITHERSBURG, Md., Jan. 14 /PRNewswire/ -- VIRxSYS Corporation, a privately held company developing gene therapies for HIV and genetic diseases, and Lentigen Corporation, a privately-owned biotechnology company focused on the manufacture and development of lentiviral vectors, today announced that they have agreed to settle the pending litigation between the two companies. The parties will dismiss all claims and counterclaims asserted in the lawsuit, which has been pending in the Circuit Court for Baltimore County in Maryland. Additional terms and conditions of the settlement are confidential.

About VIRxSYS

VIRxSYS is a private biotechnology company using proprietary lentiviral vector delivery and RNA payload platforms to develop therapies for serious human diseases. The Company's initial lentiviral delivery technology was exclusively licensed from The Johns Hopkins University and has been substantially advanced in the Company's laboratories. The RNA payload technology was acquired and has been integrated with the Company's lentiviral delivery technology. In addition to preclinical programs for genetic and other serious diseases, the Company is currently developing gene and vaccine therapies for HIV, one of which has advanced to Phase II human clinical trials. More information regarding VIRxSYS can be found at http://www.virxsys.com. Details for the Phase II study can be found at the NIH clinical trials website at clinicaltrials.gov/show/NCT00131560.

About Lentigen Corporation

Lentigen Corporation is a privately-owned biotechnology company focused on the manufacturing and development of lentiviral vectors using its proprietary gene delivery technology for a wide range of applications in biotechnology and medicine. Lentiviral vectors are highly adapted delivery vehicles that can transport genes or gene silencing sequences into cells with high efficiency and stability. Lentigen is positioning itself to become the leading provider of lentiviral vector products and services for academic, government, biotechnology and pharmaceutical researchers. For further information, visit http://www.lentigen.com.

Contact: Paul Gibney

Corinth Group Communications

Phone: (212) 255-5340

E-mail: pgibney@corinthgroup.com

Contact: Gregory Tiberend

Richard Lewis Communications, Inc.

Phone: (212) 827-0020

E-mail: gtiberend@rlcinc.com


'/>"/>
SOURCE VIRxSYS Corporation and Lentigen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... NEW YORK , April 28, 2016 /PRNewswire/ ... biotechnology acceleration company reports the Company,s CEO  was ... capital titled Accelerators Enter When VCs Fear To ... Life Science Leader magazine is an ... work for everything from emerging biotechs to Big ...
(Date:4/28/2016)... , ... April 28, 2016 , ... ... will deliver a talk on its first-in-class technologies for tissue stem cell ... Meeting on RNAiMicroRNA Biology to Reprogramming & CRISPR-based Genome Engineering in Burlington, ...
(Date:4/28/2016)... ... April 28, 2016 , ... Morris Midwest ( ... for regional manufacturers at its Maple Grove, Minnesota technical center, May 11-12. ... and Trumpf. Almost 20 leading suppliers of tooling, accessories, software and other ...
(Date:4/27/2016)... ... ... Shimadzu Scientific Instruments (SSI) will be showcasing a broad ... Expo. Shimadzu’s high-performance instruments enable laboratories to test cannabis products for potency, moisture, ... booth 1021 to learn how Shimadzu’s instruments can help improve QA/QC testing, peak ...
Breaking Biology Technology:
(Date:3/23/2016)... 2016 Einzigartige ... und Stimmerkennung mit Passwörtern     ... MESG ), ein führender Anbieter digitaler Kommunikationsdienste, ... SpeechPro zusammenarbeitet, um erstmals dessen Biometrietechnologie einzusetzen. ... Möglichkeit angeboten, im Rahmen mobiler Apps neben ...
(Date:3/22/2016)... PROVO and SANDY, ... Screening Ontario (NSO), which operates the highest sample volume ... testing, and Tute Genomics and UNIConnect, leaders in clinical ... today announced the launch of a project to establish ... testing panel. NSO has been contracted ...
(Date:3/18/2016)... March 18, 2016 --> ... Biometrics, ICT, Manned & Unmanned Vehicles, Physical infrastructure and Perimeter ... companies in the border security market and the continuing migration ... Europe has led visiongain to publish ... success. --> defence & security companies in ...
Breaking Biology News(10 mins):